SCHEMBL7239551

SCHEMBL7239551

N#Cc1cccnc1-c1cccc(N)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP4K4 O95819 4/20 0.50
HDAC1 Q13547 1/20 0.45
AXL P30530 2/20 0.45
MKNK2 Q9HBH9 2/20 0.45
MEN1 O00255 1/20 0.45
PSIP1 O75475 1/20 0.45
MKNK1 Q9BUB5 1/20 0.45
CNR2 P34972 1/20 0.44
NPC1 O15118 1/20 0.42
KCNH2 Q12809 1/20 0.42
ALDH1A1 P00352 1/20 0.41
POLB P06746 1/20 0.41
GFER P55789 1/20 0.41
PLAUR Q03405 1/20 0.40
MAOA P21397 1/20 0.40
CLK4 Q9HAZ1 1/20 0.40
ADORA2A P29274 2/20 0.40
ADORA1 P30542 2/20 0.40
AURKA O14965 1/20 0.40
MECP2 P51608 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17116598 0.85 CNR2 (0.47) HDAC1CNR2KCNH2ALDH1A1CLK4
SCHEMBL3290050 0.81 ADORA2B (0.48) MAP4K4HDAC1CNR2KCNH2CLK4
SCHEMBL17116730 0.81 CLK4 (0.47) HDAC1CNR2KCNH2ALDH1A1CLK4
SCHEMBL1146096 0.79 HDAC1 (0.51) HDAC1CNR2ALDH1A1PLAURCLK4
SCHEMBL29768457 0.79 HDAC1 (0.51) HDAC1CNR2ALDH1A1PLAURCLK4
SCHEMBL17116398 0.78 KDM4E (0.44) HDAC1MEN1CNR2KCNH2ALDH1A1
SCHEMBL5826057 0.78 HDAC1 (0.50) HDAC1CNR2ALDH1A1PLAURCLK4
SCHEMBL27339880 0.78 MAP4K4 (0.58) MAP4K4AXLMKNK2MEN1PSIP1
SCHEMBL16682155 0.77 IKBKB (0.50) HDAC1CNR2TRPV1
SCHEMBL17116579 0.77 CNR2 (0.41) HDAC1CNR2NPC1KCNH2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6521643-B1 Prevention and/or treatment of nitric oxide synthasey medi-ated diseases such as adult respiratory distress syndrome, myocarditis, synovitis, septic shock, diabetes, ulcerative colitis, cerebral infarction, osteoarthritis FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-02-18 US disclosed
EP-1157022-A1 PYRIDINE COMPOUNDS AND THEIR PHARMACEUTICAL USE FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-11-28 EP disclosed
WO-2000049015-A1 PYRIDINE COMPOUNDS AND THEIR PHARMACEUTICAL USE FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2000-08-24 WO disclosed